CO214 Model Predictions for Lifetime Health Benefits of Mobocertinib and Current Treatment Options in Post-Platinum Patients with Locally Advanced or Metastatic NSCLC Harboring Egfr Exon 20 Insertion Mutation in China
Jun 1, 2023, 00:00 AM
10.1016/j.jval.2023.03.2439
https://www.valueinhealthjournal.com/article/S1098-3015(23)02629-3/fulltext
Section Title :
Section Order :
11678
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)02629-3&doi=10.1016/j.jval.2023.03.2439